Philip James Wealth Mangement LLC Purchases 67,253 Shares of Pfizer Inc. $PFE

Key Points

• Philip James Wealth Management LLC increased its holdings in Pfizer Inc. by 20.3%, acquiring an additional 67,253 shares to own a total of 398,719 shares, valued at approximately $9.67 million.
• Analysts have provided mixed ratings for Pfizer, with a consensus rating of "Hold" and an average target price of $28.29, indicating cautious sentiment among market watchers.
• Pfizer reported earnings of $0.78 EPS for the last quarter, exceeding expectations, and its revenue grew by 10.3% year-over-year, totaling $14.65 billion.

Philip James Wealth Mangement LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 20.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 398,719 shares of the biopharmaceutical company's stock after acquiring an additional 67,253 shares during the quarter. Pfizer accounts for approximately 1.2% of Philip James Wealth Mangement LLC's investment portfolio, making the stock its 16th largest holding. Philip James Wealth Mangement LLC's holdings in Pfizer were worth $9,665,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter valued at about $27,000. Bayforest Capital Ltd purchased a new position in Pfizer in the first quarter valued at about $28,000. North Capital Inc. purchased a new position in Pfizer in the first quarter valued at about $28,000. WPG Advisers LLC purchased a new position in Pfizer in the first quarter valued at about $35,000. Finally, Horizon Financial Services LLC purchased a new position in Pfizer in the first quarter valued at about $35,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday. UBS Group restated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $28.29.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.21 on Thursday. The business's 50 day moving average price is $24.59 and its 200 day moving average price is $24.14. The firm has a market cap of $154.68 billion, a P/E ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.